Real-World Multicenter Registry to Determine Management and Quality of Care of Patients with Type 2 Diabetes, Hypertension, Heart Failure and/or Chronic Kidney Diseases in China (iCaReMe China).

INTRODUCTION

This article describes the study rationale and design of the real-world multicenter registry study iCaReMe China.

METHODS

iCaReMe China is a prospective, multicentric, observational registry study aiming to understand the real-world characteristics of patients with type 2 diabetes (T2D) and/or hypertension (HTN) [combined chronic kidney disease (CKD)] and/or heart failure (HF) and/or CKD, which may provide some evidence for improving quality of care and outcomes of T2D and/or HTN and/or HF and/or CKD in China. A total of approximately 19,000 subjects will be recruited from 110 participating sites in China. Patients will be enrolled in four disease cohorts based on the primary disease conditions. The primary outcome is to describe the sociodemographic, clinical characteristics, disease management patterns, healthcare resource utilization, and clinical outcomes.

CONCLUSION

iCaReMe China aims to describe the real-world characteristics and treatment patterns of patient with T2D and/or HTN (combined CKD) and/or HF and/or CKD. The data from this prospective registry study will facilitate a better understanding of management strategies, the variations across and within different regions, and associated patient outcomes in China.

TRIAL REGISTRATION NUMBER

ChiCTR2300073764.